Working... Menu

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00238628
Recruitment Status : Completed
First Posted : October 13, 2005
Last Update Posted : July 20, 2010
Ligand Pharmaceuticals
Information provided by:
Stanford University

Tracking Information
First Submitted Date  ICMJE October 11, 2005
First Posted Date  ICMJE October 13, 2005
Last Update Posted Date July 20, 2010
Study Start Date  ICMJE April 2004
Actual Primary Completion Date April 2005   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 24, 2009)
  • Overall response rate (RECIST CRITERIA), time to progression, toxicity [ Time Frame: Completed 9/2005 ]
  • Pharmacokinetic analysis [ Time Frame: Completed 12/2005 ]
  • Median survival [ Time Frame: Calculated Spring 2008 ]
  • Overall response rate (RECIST CRITERIA), time to progression, toxicity [ Time Frame: Final analysis Spring 2008 ]
Original Primary Outcome Measures  ICMJE Not Provided
Change History Complete list of historical versions of study NCT00238628 on Archive Site
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
Official Title  ICMJE A Phase I/II Study of Bexarotene in Combination With ZD 1839 (IRESSA) in the Third Line Treatment of Non-Small Cell Lung Cancer (NSCLC)
Brief Summary The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lung Cancer
Intervention  ICMJE
  • Drug: Bexarotene
  • Drug: Iressa
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: May 22, 2008)
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE December 2005
Actual Primary Completion Date April 2005   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:- Patients must have histologically or cytologically confirmed NSCLC which is stage IIIB with malignant pleural effusion or stage IV and have failed therapy with at least a standard first line chemotherapy regimen, or be intolerant of standard chemotherapy.

  • Patients may have non-measurable disease, or measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan).
  • Patients with asymptomatic or treated brain metastases will be eligible if they last received therapy (including steroids) > 4 weeks from study entry and are felt to have a low likelihood of rapid deterioration from their brain metastases.
  • Patients must have had at least 1 prior systemic therapy for NSCLC, or have shown intolerance to chemotherapy. Patients may not have received prior therapy with bexarotene, ZD1839, or erlotinib (Tarceva).
  • At least 4 weeks must have elapsed from the time of major surgery and patients must have recovered from the effects of any significant procedure.
  • A three week interval must have elapsed from the last dose of chemotherapy (30 days for investigational therapy), prior to beginning protocol therapy (6 weeks if nitrosoureas or mitomycin C). Palliative radiotherapy to bony sites of disease is allowed while on trial and up to time of enrollment provided patient has no significant side effects from the radiotherapy.
  • Age >= 18 years.
  • Life expectancy > 2 months.
  • ECOG performance status 0-2.
  • Women of childbearing potential must have a negative pregnancy test (serum ß HCG with a sensitivity of at least 50 mlU/L) within 7 days prior to initiation of treatment and must have used 2 reliable forms of effective contraception used simultaneously or have been sexually abstinent for at least 4 weeks prior to the negative pregnancy test through entry in the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

    • Retinoid class agents are known teratogens.
  • Female patients and male patients with female partners of childbearing potential must agree to sexual abstinence or to practice 2 reliable forms of effective contraception used simultaneously during the entire period of bexarotene capsule treatment and for at least 1 month after treatment is discontinued. Male patients must agree to use condoms if they have a female sexual partner who is, or may become, pregnant.
  • Patients must have normal organ and marrow function as defined below:

    • leukocytes >= 3,000/ul
    • absolute neutrophil count >= 1,500/ul
    • platelets >= 100,000/ul
    • total bilirubin within normal institutional limits
    • AST(SGOT)/ALT(SGPT) <= 2.5 X institutional upper limit of normal
    • creatinine within normal institutional limits OR calculated creatinine clearance >= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
    • triglycerides and cholesterol levels which are within normal limits or "normalized" with medication
  • Patients may take the following agents, but with caution due to interactions with P450 metabolism: dexamethasone, protease inhibitors, ketoconazole and other azole antifungals, erythromycin and other macrolides antibiotics, grapefruit juice, other retinoid class drugs, beta-carotene compounds, and agents which enhance insulin secretion and sensitivity. They may not take phenytoin, carbamazepine, rifampicin, barbiturates, or St. John's Wort while on study.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:- Insulin dependent diabetes

  • Thyroid disease
  • Patients may not have had chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study and must have recovered from adverse events due to agents administered more than 4 weeks earlier. Palliative radiotherapy is allowed to bony sites of disease.
  • Patients may not be receiving any other investigational agents or have received any within 30 days prior to day 1 of study.
  • Patients with known symptomatic brain metastases are excluded from this clinical trial because of their poor prognosis, those with treated, asymptomatic brain metastases are eligible proved they have not required any therapy including steroids for at least 4 weeks.
  • Patients with a history of allergic reactions or sensitivity attributed to compounds of similar chemical or biologic composition to bexarotene and ZD1839 are excluded.
  • Patients with triglycerides or cholesterol levels which are not within normal limits or "normalized" with medication will be excluded.
  • Patients will be excluded for uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patients with another active malignancy except for non-melanoma skin cancers are excluded.
  • Pregnant or breastfeeding women are excluded.
  • Patients with risk factors for pancreatitis are excluded such as a history of pancreatitis, significant alcohol consumption or other factors which are deemed to put them at high risk.
  • Patients taking systemic vitamin A in doses exceeding 15,000 IU/day within 14 days of study entry will be excluded.
  • Patients who are unwilling to minimize exposure to ultraviolet light (sunlight) while on bexarotene will be excluded.
  • Patients MAY NOT TAKE GEMFIBROZIL while on study due to interactions with bexarotene
  • Patients may not take phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort while on the study.
  • Patients with any evidence of clinically active interstitial lung disease will be excluded (patients with chronic stable radiographic changes who are asymptomatic need not be excluded)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00238628
Other Study ID Numbers  ICMJE LUN0005
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Charlotte D Jacobs, Stanford University School of Medicine
Study Sponsor  ICMJE Stanford University
Collaborators  ICMJE
  • Ligand Pharmaceuticals
  • AstraZeneca
Investigators  ICMJE
Principal Investigator: Charlotte D Jacobs Stanford University
PRS Account Stanford University
Verification Date July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP